Novo Nordisk is rolling out a tablet version of Ozempic (semaglutide) across the United States starting May 4, bringing a well-known injectable treatment into a pill format. It sounds simple—same drug, different delivery—but in reality, getting a peptide-based therapy into an oral form has been a long-standing scientific hurdle, so this is… kind of a big deal. For years, Ozempic has been associated with weekly injections, widely prescribed for adults with Type 2 diabetes not just to control blood sugar but also to reduce the risk of serious cardiovascular events like heart attacks and strokes.

Tempus AI, Inc. (NASDAQ: TEM) is moving deeper into the clinical workflow layer with the launch of an automated update service designed to keep cancer care aligned with the latest medical guidance in real time. The system introduces what the company describes as an “active follow-up” model, where patients remain continuously monitored after their initial genomic profiling rather than relying on a static report that can quickly lose relevance. At the center of this approach is an integrated workflow within Tempus’ physician platform, Hub.